Prabhudas Lilladher's research report on Fortis Healthcare
Fortis Healthcare (FORH) reported strong EBITDA of Rs4.9bn, up 43% YoY, marking strong beat across segments. Though hospital margin has improved by 360bps bps YoY over FY23-25 to ~20%, we see further scope for improvement aided by 1) improving case and payor mix, 2) cost rationalization initiatives and ramp-up of Manesar unit, and 3) new brownfield bed additions. Additionally, we expect margin to expand further, driven by the recent acquisition of Shrimann Hospital and the O&M agreement with Gleneagles. Our FY26E and FY27E EBITDA stands increased by 6%. We expect EBITDA to clock 24% CAGR over FY25-27E.
Outlook
At CMP, the stock is trading at 28x EV/EBITDA on FY27E, adjusted for Agilus stake. Maintain ‘BUY’ rating with revised TP of Rs1,000/share, valuing the hospital segment at 32x and diagnostic segment at 30x EV/EBITDA on FY27E.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.